Mydecine Innovations Group Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mydecine Innovations Group Inc.
Sumitomo, Otsuka Both Stand To Gain From CNS Partnership
Sumitomo’s Sunovion has made particular headway in the TAAR1 agonist field and stands to benefit from Otsuka’s CNS expertise and overseas marketing heft.
Tech Transfer Roundup: Mydecine, Johns Hopkins Pair Up To Study Psychedelics
BioMed X teams with J&J on inflammation, drug delivery research. Stem cell firm Calidi inks licensing deals with U. of Chicago, City of Hope and Northwestern. MD Anderson teams with Blueprint and Hummingbird.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- ALT House Cannabis Inc.
- Mydecine Health Sciences
- Mindleap Health and NeuroPharm
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.